To include your compound in the COVID-19 Resource Center, submit it here.

Cash only, please

Stock is often the currency of choice in life science acquisitions, as CEOs like to leave the cash untouched to ensure they have enough working capital to fund the combined entity. But Cephalon Inc. is forking over $450 million in cash for Group Lafon, even though CEPH's shares have

Read the full 499 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers